Teva Pharmaceutical Industries Limited (TEVA) Earning Somewhat Negative Media Coverage, Report Shows
Media stories about Teva Pharmaceutical Industries Limited (NYSE:TEVA) have trended somewhat negative on Thursday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teva Pharmaceutical Industries Limited earned a coverage optimism score of -0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 43.0993014329992 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- IBI: Teva layoffs ready investors for offering (globes.co.il)
- Teva Pharmaceutical Industries : plans over 1,000 layoffs in Israel (4-traders.com)
- Inside Teva’s 3Q17 Performance (finance.yahoo.com)
- Why Teva Will Be Hard Pressed to Maintain Its Dividend in the Long Term (finance.yahoo.com)
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) – Hot Mover to Watch – Alpha Beta Stock (alphabetastock.com)
A number of research analysts have recently commented on TEVA shares. BidaskClub lowered Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 16th. Citigroup Inc. lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $32.00 to $19.00 in a report on Wednesday, August 16th. Credit Suisse Group reissued an “outperform” rating and set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Cantor Fitzgerald set a $17.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a report on Monday, September 11th. Finally, Oppenheimer Holdings, Inc. lowered Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and set a $41.00 price objective on the stock. in a report on Thursday, August 3rd. Seven research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and a consensus target price of $21.88.
Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up $0.15 during trading hours on Thursday, hitting $13.48. The stock had a trading volume of 11,806,900 shares, compared to its average volume of 15,437,631. Teva Pharmaceutical Industries Limited has a one year low of $10.85 and a one year high of $38.49. The firm has a market cap of $13,543.28, a price-to-earnings ratio of 3.08 and a beta of 0.52. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 2.52%. The ex-dividend date is Monday, November 27th. Teva Pharmaceutical Industries Limited’s payout ratio is presently -15.80%.
WARNING: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/23/teva-pharmaceutical-industries-limited-teva-earning-somewhat-negative-media-coverage-report-shows.html.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.